Navigation Links
Stuy in NEJM: New therapy prevents heart failure
Date:9/1/2009

Patients who had a cardiac resynchronization device combined with a defibrillator (CRT-D) implanted had a 34 percent reduction in their risk of death or heart failure when compared to patients receiving only an implanted cardiac defibrillator (ICD), according to a landmark study published online today in the New England Journal of Medicine and presented today at the European Society of Cardiology Congress (ESC) in Barcelona, Spain. The overall benefit observed from resynchronization therapy was driven by a 41 percent reduction in heart failure. Women who received CRT-D had an "astonishing" 63 percent reduction in their risk of heart failure.

About one million cardiac patients in the United States die each year from either electrical, heart rhythm disorders that result in sudden cardiac death or from mechanical disorders where the heart's pumping ability is impaired (heart failure), according to the study authors.

In 2002, Arthur Moss, M.D., professor of Medicine at the University of Rochester Medical Center, and the MADIT (Multicenter Automatic Defibrillator Implantation Trial) research group showed that an implanted defibrillator, or ICD, reduced the risk of death by 31 percent in cardiac patients as part of the MADIT-II trial. This therapy was soon approved by the U.S. Food and Drug Administration and became part of professional guidelines from the American Heart Association, the American College of Cardiology and the Heart Rhythm Society. Long-term follow-up studies showed, however, that ICDs were so effective at preventing sudden death that patients lived longer and were subsequently at increased risk for heart failure. This created an urgent need to better address both risks in tandem.

Cardiac resynchronization therapy (CRT) is currently approved for treatment only for patients with symptoms of severe heart failure (New York Heart Association [NYHA] class III and IV) in whom it reduces symptoms by improving the mechanic
'/>"/>

Contact: Greg Williams
Greg_Williams@urmc.rochester.edu
585-273-1757
University of Rochester Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. NEJM: Low-fat diets not best for weight loss: New study by Ben-Gurion U. of the Negev
2. Promise of nanodiamonds for safer gene therapy
3. Chemotherapy Linked to Sleep-Wake Cycle Disruptions
4. U.S. Compression Therapy Market to Reach $1.16 Billion in 2015, Finds Frost & Sullivan
5. The benefits of reperfusion therapy
6. Chemotherapy for breast cancer is associated with disruption of sleep-wake rhythm in women
7. CPF Submits Comments to CMS to Save Only Effective Therapy Available to PF Patients
8. Secca(R) Therapy - An Effective and Minimally Invasive Option for Treating Bowel Incontinence - Launched in the US
9. Varian Medical Systems Adds RapidArc(R) and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clinics
10. Researchers find high-dose therapy for liver disease not effective
11. NIH grant advances Tay-Sachs disease gene therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... (PRWEB) July 12, 2014 Demand Response ... with considerable benefits in reducing the imbalance between energy ... grid appliances have been rolled out (due to increasing ... Infrastructure (AMI). This helps in controlling residential appliances and ... growing in the North American region, and with government ...
(Date:7/12/2014)... 12, 2014 Tylenol lawsuits ( ... move forward in the federal multidistrict litigation underway ... Bernstein Liebhard LLP reports. According to a filing ... F. Stengel has ordered the deposition of a ... found that the witness’s testimony concerning the marketing ...
(Date:7/12/2014)... News) -- Burn injuries increase in the summer as people ... experts. Among those most vulnerable to these seasonal fire hazards: ... often get burned by putting their hands on the side ... burn unit at Loyola University Medical Center in Maywood, Ill., ... of ,When you play with fire, you get burned, is ...
(Date:7/12/2014)... “After my mom’s stroke, she loss the use of ... the use of his left side. Eating became a difficult task ... people like them enjoy eating again,” said an inventor, from Fayetteville, ... CAROL HALL PLATE (P C H PLATE). , The PATRICIA CAROL ... to eat for individuals who suffer from stroke, experience tremors or ...
(Date:7/12/2014)... 2014 With prom shopping reaching its ... retailer, is ready to showcase its new and trendy ... of evening dresses in its online shop. Additionally, it ... for these elegant gowns. According to the company’s sales ... July 26, 2014. , He says, “Now, worldwide ...
Breaking Medicine News(10 mins):Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Demand Response Management System Worth $12,522.4 Million by 2019 - New Report by MicroMarket Monitor 4Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:Burn Injuries More Common in Summer 2Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2
... Va. (April 13, 2009) While the number of ... registry still only includes 38 percent of licensed drivers, according ... year. Yet, according to a new survey of Americans, ... even if their family disagrees. , "The number of ...
... Rx, Inc., the,pioneering force in measuring the impact of ... physicians, announces that Mark,Degatano has joined the company as ... a newly-created position that expands and,strengthens Impact Rx,s business ... his new role Degatano will lead programs at the ...
... ... April 13, 2009 -- Accept an illicit injection and the result ... Coalition for Injectable Safety. The recent death of a Bronx, NY ... her thighs and buttocks is an unfortunate and repeating pattern of incidents ...
... FARMINGDALE, N.Y., April 13 Misonix, Inc. (Nasdaq: ... medical device technology, which in Europe is used for ... health conditions, has entered into a new, three year, ... Avanco Sistemas Medicos, based in Barcarena, Portugal, for the ...
... wide today as it was in the early ,90s, study ... with lung cancer are less likely than white patients to ... Disparities in lung cancer treatments were as large in 2002 ... there have been efforts to decrease those inequalities in treatment, ...
... As all eyes turn to the health reform debate in ... of California - will urge that "everything be on the ... D.C. Mr. Bodaken will participate in a keynote panel kicking ... that begins with an address by Dora Hughes, counselor to the ...
Cached Medicine News:Health News:While majority of Americans express interest in organ and tissue donation, few register 2Health News:Impact Rx, Inc. Names Mark Degatano as Vice President, Business Development, Key Client Initiatives 2Health News:Consumer Alert: Illegal Silicone Injections Result in Death 2Health News:Consumer Alert: Illegal Silicone Injections Result in Death 3Health News:Consumer Alert: Illegal Silicone Injections Result in Death 4Health News:Misonix Announces New Distribution Agreement for Portugal 2Health News:Misonix Announces New Distribution Agreement for Portugal 3Health News:Blacks Less Likely to Get Optimal Lung Cancer Treatment 2Health News:Blue Shield of California CEO to Speak at World Health Care Congress in Washington D.C. 2
(Date:7/11/2014)... DIEGO , July 11, 2014 Neurelis, ... Corp. ("Biotie") to end the option held by Biotie ... commence further development of NRL-1 (intranasal diazepam) for pediatric ... Over the past year, Biotie has advanced ... in preparation for the pivotal clinical work required for ...
(Date:7/10/2014)... 10, 2014 Integrated Silicon Solution, Inc. (Nasdaq: ... and analog IC solutions, today announced that it will ... 2014, at 7:00 a.m. Pacific Time (10:00 a.m. Eastern ... fiscal 2014 third quarter ended June 30, 2014. ... 1-888-556-4997 before 6:50 a.m. Pacific time on July 24, ...
(Date:7/10/2014)...   Ventana Medical Systems, Inc.  (Ventana), a member ... into an agreement with Merck KGaA, Darmstadt, ... the United States and ... biopharmaceutical division on the development and commercialization of a ... proprietary diagnostic assays. In alignment with Merck KGaA,s strategic ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
... Specialty Silicone Fabricators (SSF), a leading global ... inaugurated its state-of-the-art 102,000 square-foot facility today in ... facility joins all Paso Robles departments, operations and ... Tustin, Calif. and Elk Rapids, Mich. The new ...
... Ohio, May 29, 2012  Cardinal Health Specialty Solutions ... technology system that makes it easier for payors ... that improve the quality and cost of caring ... rheumatoid arthritis. One of Cardinal Health ...
Cached Medicine Technology:Specialty Silicone Fabricators Inaugurates New State-of-the-Art Facility in Paso Robles 2Cardinal Health Specialty Solutions Launches PathWare™ Decision Support Transaction Solutions 2Cardinal Health Specialty Solutions Launches PathWare™ Decision Support Transaction Solutions 3
Used for traversing and exploring urethral strictures. The malleable tip can be shaped to desired configuration. The proximal end is threaded to attach to standard followers. Supplied sterile in peel...
Used to dilate the male or female urethra to treat stricture disease. Supplied sterile in peel-open packages. Intended for one-time use....
The balloon catheter is designed to pass over a previously placed .015 inch diameter wire guide included. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
Medicine Products: